Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Court Rules In Favor Of Boston Scientific In Johnson & Johnson Litigation

RELATED NEWS
Trade BSX now with 

Medical device maker Boston Scientific Corp. (BSX: Quote) announced that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Healthcare giant Johnson & Johnson (JNJ: Quote) to be invalid and entered judgment in favor of Boston Scientific.

Under the 2008 patent infringement suit, Johnson & Johnson alleged that Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146. The patents relate to the use of a drug on a drug-eluting stent.

Click here to receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs. Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.